A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
Completed
- Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Interventions
- Other: Cosentyx
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05388916
- Locations
- ๐จ๐ณ
Novartis Investigative Site, Shijiazhuang, China
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam
Phase 3
Completed
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Genetic: OAV101
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT05386680
- Locations
- ๐บ๐ธ
Boston Childrens Hospital, Boston, Massachusetts, United States
๐บ๐ธChild Hosp Of The Kings Daughters, Norfolk, Virginia, United States
๐บ๐ธUniversity of Wisconsin Madison Medical School, Madison, Wisconsin, United States
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Phase 2
Active, not recruiting
- Conditions
- Chronic Myelogenous Leukemia - Chronic Phase
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT05384587
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธLundquist Inst BioMed at Harbor, Torrance, California, United States
๐บ๐ธRocky Mountain Cancer Centers, Boulder, Colorado, United States
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Phase 3
Recruiting
- Conditions
- Giant Cell Arteritis
- Interventions
- Drug: Placebo to match Secukinumab, s.c.
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 146
- Registration Number
- NCT05380453
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Wuerzburg, Germany
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Active, not recruiting
- Conditions
- Active Secondary Progressive Multiple Sclerosis
- Interventions
- Other: siponimod
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT05376579
- Locations
- ๐ฎ๐น
Novartis Investigative Site, Novara, Italy
Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.
Completed
- Conditions
- Migraine
- Interventions
- Other: Erenumab
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT05375097
- Locations
- ๐บ๐ธ
Novartis Investigative Site, East Hanover, New Jersey, United States
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Phase 1
Withdrawn
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05367401
An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Other: Secukinumab
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 767
- Registration Number
- NCT05368818
- Locations
- ๐บ๐ธ
Novartis Investigative Site, East Hanover, New Jersey, United States
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)
Completed
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- Other: CAR-TOther: Allo-HSCT cohort
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160602
- Registration Number
- NCT05366257
- Locations
- ๐บ๐ธ
Novartis Investigative Site, East Hanover, New Jersey, United States
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvioยฎ) and Other Lipid Lowering Treatments in a Real-world Setting
Recruiting
- Conditions
- Hypercholesterolemia
- Interventions
- Other: Inclisiran
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2030
- Registration Number
- NCT05362903
- Locations
- ๐ฉ๐ช
Novartis Investigative Site, Zwiesel, Germany
ยฉ Copyright 2025. All Rights Reserved by MedPath